Patient Characteristics
| BB-10010 dose (μg/kg) | 0 | 30 | 100 |
| No. | 9 | 11 | 10 |
| Age, mean (range) | 45 (29-63) | 49 (34-62) | 56 (41-69) |
| Mean performance status | 0.7 | 0.2 | 0.6 |
| Median performance status (range) | 0.5 (0-2) | 0 (0-1) | 1 (0-2) |
| Number of sites of secondary disease | |||
| 1 | 6 | 8 | 6 |
| 2 | 1 | 2 | 2 |
| 3 | 2 | 0 | 1 |
| >3 | 0 | 1 | 1 |
| No. of patients with secondary disease in bone* | 5 | 4 | 4 |
| No. of patients with definable BM involvement-151 | 2 | 0 | 0 |
| No. of patients completing 6 cycles-152 | 7 | 10 | 10 |
| Previous adjuvant CMF chemotherapy | 3 | 3 | 2 |
| Previous endocrine therapy | 5 | 5 | 7 |
| BB-10010 dose (μg/kg) | 0 | 30 | 100 |
| No. | 9 | 11 | 10 |
| Age, mean (range) | 45 (29-63) | 49 (34-62) | 56 (41-69) |
| Mean performance status | 0.7 | 0.2 | 0.6 |
| Median performance status (range) | 0.5 (0-2) | 0 (0-1) | 1 (0-2) |
| Number of sites of secondary disease | |||
| 1 | 6 | 8 | 6 |
| 2 | 1 | 2 | 2 |
| 3 | 2 | 0 | 1 |
| >3 | 0 | 1 | 1 |
| No. of patients with secondary disease in bone* | 5 | 4 | 4 |
| No. of patients with definable BM involvement-151 | 2 | 0 | 0 |
| No. of patients completing 6 cycles-152 | 7 | 10 | 10 |
| Previous adjuvant CMF chemotherapy | 3 | 3 | 2 |
| Previous endocrine therapy | 5 | 5 | 7 |